Dr. Dennis Donohoe

• 
  www.svmb.org/annual_meeting/faculty.cfm - [Cached Version]
  Published on: 5/22/2008    Last Visited: 5/22/2008  

  Dennis Donohoe, MD, Cordis Corporation

• 
  www.investor.jnj.com/textonly/releasedetail.cfm?Release - [Cached Version]
  Published on: 10/24/2006    Last Visited: 2/2/2008  

  Dennis Donohoe, M.D., vice president, Worldwide Clinical and Regulatory Affairs, Cordis Corporation, said, "We know that thrombosis can and do occur with interventional cardiovascular procedures.
  ...
  "The independent analysis by HCRI per the ARC definitions evaluated the data using two definitions of thrombosis - any and definite/probable thrombosis - and there is no difference versus bare-metal stents in the rate of thromboses at four years by either version of this standardized definition," said Dr. Donohoe.

• 
  www.ptinews.com/pti/ptisite.nsf/3bd160b7df5ffc326525709 - [Cached Version]
  Published on: 10/11/2004    Last Visited: 10/22/2005  

  Dennis Donohoe, M.D., vice president of worldwide clinical research and regulatory affairs for Cordis Corporation.

• 
  www.eurekalert.org/pub_releases/2008-05/epr-esi051408.p - [Cached Version]
  Published on: 5/14/2008    Last Visited: 5/17/2008  

  "The safety and efficacy of the CYPHER SELECT(TM) + (Plus) Stent in treating patients with arterial obstructions in arteries where regulatory approvals have been approved has been proven through a robust clinical trial program," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical Affairs, Cordis Corporation.

• 
  www.ccvi-online.com/About/News/Pages/Sirolimus-elutings - [Cached Version]
  Published on: 5/14/2008    Last Visited: 7/12/2008  

  "The safety and efficacy of the CYPHER SELECTâ„¢ + (Plus) Stent in treating patients with arterial obstructions in arteries where regulatory approvals have been approved has been proven through a robust clinical trial program," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical Affairs, Cordis Corporation.

• 
  www.investor.jnj.com/textonly/releasedetail.cfm?Release - [Cached Version]
  Published on: 10/23/2007    Last Visited: 2/2/2008  

  "The PRECISE® Stent has been studied extensively in a wide range of high-risk patients and we intend to continue building upon this important body of clinical evidence," said Dr. Dennis Donohoe, Vice President, Worldwide Clinical Affairs, Cordis Corporation.

• 
  www.aimquoted.com/news/story_display.php?story_id=942 - [Cached Version]
  Published on: 4/19/2007    Last Visited: 4/27/2007  

  "With SLEEKTM and the expansion of our existing SAVVY(R) product line with SAVVY (R) LONG , we are delivering on our commitment to increase the depth and breadth of our peripheral portfolio for physicians and the millions of patients with peripheral vascular disease that they treat," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical and Medical Affairs, Cordis Corporation.

• 
  www.dimag.com/pacswebcardio/pressreleases/showPressRele - [Cached Version]
  Published on: 4/18/2007    Last Visited: 4/19/2007  

  "With SLEEK(TM) and the expansion of our existing SAVVY(R) product line with SAVVY(R) LONG, we are delivering on our commitment to increase the depth and breadth of our peripheral portfolio for physicians and the millions of patients with peripheral vascular disease they treat," said Dennis Donohoe, M.D., Vice President, Worldwide Clinical and Medical Affairs, Cordis Corporation.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 4/18/2007    Last Visited: 4/18/2007  

  Dennis Donohoe, M.D., Vice President, Worldwide Clinical and Medical

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/w - [Cached Version]
  Published on: 10/23/2007    Last Visited: 10/27/2007  

  body of clinical evidence," said Dr. Dennis Donohoe, Vice President, Worldwide Clinical Affairs, Cordis Corporation.

Page:  1 2 3 4 5